ZSCAN16 Antibody

What is ZSCAN16 and what are its known functions?

ZSCAN16 (also known as ZNF392 or ZNF435) is a zinc finger protein that belongs to the zinc finger and SCAN domain-containing (ZSCAN) transcription factors, a subgroup of the Zinc finger (ZNF) family. It plays crucial roles in:

• Telomere maintenance and genome stability

• DNA replication and repair processes

• Cell division and aging processes

• Transcriptional regulation

The protein is expressed in various tissues and has been shown to be capable of homoassociation. Research indicates its importance in cancer biology, particularly in hepatocellular carcinoma where it mediates transcriptional activation of TBC1D31 .

How do I select the appropriate ZSCAN16 antibody for my research application?

Selection should be based on your specific experimental needs:

Consider the host species (typically rabbit for polyclonal, mouse for monoclonal) and the species reactivity needed for your experimental model. For example, if working with human HCC cell lines like Hep3B or PLC/PRF/5, ensure human reactivity .

What are the optimal storage conditions for ZSCAN16 antibodies?

Most ZSCAN16 antibodies are supplied in liquid form containing buffer solutions such as phosphate buffered saline (PBS) with stabilizers.

Recommended storage conditions:

• Store at -20°C or -80°C upon receipt

• Avoid repeated freeze-thaw cycles

• Typical storage buffers contain 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Working dilutions can typically be stored at 4°C for up to one week

What are validated protocols for ZSCAN16 detection in hepatocellular carcinoma samples?

For HCC research, the following protocols have been validated:

Western Blot Analysis:

• Extract proteins from HCC cell lines (e.g., Hep3B, PLC/PRF/5) or tissue samples

• Load 20-30μg protein per lane on SDS-PAGE gel

• Transfer to PVDF membrane

• Block with 5% non-fat milk in TBST

• Incubate with ZSCAN16 antibody (1:500-1:3000 dilution)

• Detect with appropriate secondary antibody and visualization system

• Normal liver cell line THLE-2 can serve as a comparison control

Immunohistochemistry:

• Section formalin-fixed, paraffin-embedded HCC tissues (4-6μm)

• Perform antigen retrieval (typically citrate buffer, pH 6.0)

• Block endogenous peroxidase activity

• Incubate with ZSCAN16 antibody (1:100-1:300)

• Use adjacent non-cancerous liver tissue as control

• Quantify staining intensity for comparison between tumor and normal tissues

How can I evaluate ZSCAN16 expression correlation with clinical parameters in cancer studies?

Multiple approaches have been validated in recent research:

• Transcriptomic Analysis:

  • Analyze ZSCAN16 expression in public databases like TCGA

  • Compare expression levels between tumor and normal tissues

  • Correlate with clinical parameters like tumor stage and survival

• Tissue Microarray Analysis:

  • Use IHC to evaluate ZSCAN16 protein levels in tumor samples

  • Score staining intensity (0-3+)

  • Correlate with clinicopathological features

• Survival Analysis:

  • Divide patients into high and low ZSCAN16 expression groups (using median expression as cutoff)

  • Perform Kaplan-Meier survival analysis

  • Apply Cox regression for multivariate analysis

Research has shown that high ZSCAN16 expression correlates with poor prognosis in hepatocellular carcinoma patients .

How do I design experiments to investigate ZSCAN16's role in transcriptional regulation?

Based on recent findings of ZSCAN16's role as a transcription factor, a comprehensive experimental design would include:

• ChIP-qPCR Analysis:

  • Crosslink protein-DNA complexes in target cells

  • Immunoprecipitate with ZSCAN16 antibody (recommended dilution 5μg per IP)

  • Identify DNA binding sites through qPCR

  • Research has confirmed ZSCAN16 binding to the TBC1D31 promoter using this method

• Dual-Luciferase Reporter Assay:

  • Clone the promoter region of potential target genes into a luciferase reporter vector

  • Co-transfect with ZSCAN16 expression vector or siRNA

  • Measure luciferase activity to quantify transcriptional effects

  • Include mutated binding site controls

• RNA-Seq after ZSCAN16 Manipulation:

  • Perform ZSCAN16 knockdown or overexpression

  • Conduct RNA-seq to identify global transcriptional changes

  • Validate key targets using RT-qPCR

This approach has successfully identified TBC1D31 as a transcriptional target of ZSCAN16 in hepatocellular carcinoma .

What is the relationship between ZSCAN16 and its antisense RNA (ZSCAN16-AS1) in cancer progression?

The relationship between ZSCAN16 and ZSCAN16-AS1 represents a complex regulatory mechanism in cancer:

• Expression Patterns:

  • Both ZSCAN16 and ZSCAN16-AS1 are upregulated in hepatocellular carcinoma

  • ZSCAN16-AS1 is also overexpressed in melanoma

  • Their expression levels may be co-regulated or independent

• Functional Relationship:

  • ZSCAN16 functions as a transcription factor activating genes like TBC1D31

  • ZSCAN16-AS1 functions as a competing endogenous RNA (ceRNA)

  • In melanoma, ZSCAN16-AS1 sponges miR-503-5p to upregulate ARL2

  • In HCC, ZSCAN16-AS1 sponges miR-181c-5p to regulate SPAG9

• Experimental Approach to Study Their Relationship:

  • Simultaneous knockdown/overexpression experiments

  • Co-expression analysis in patient samples

  • Investigation of potential regulatory feedback loops

Research indicates they may contribute to cancer progression through different but potentially complementary mechanisms .

How can ZSCAN16 antibodies be utilized in studying telomere maintenance mechanisms?

Given ZSCAN16's involvement in telomere maintenance, the following experimental approaches are recommended:

• Co-Immunoprecipitation (Co-IP):

  • Use ZSCAN16 antibody to pull down protein complexes

  • Identify telomere-associated proteins (e.g., shelterin complex components)

  • Western blot or mass spectrometry analysis of binding partners

• Chromatin Immunoprecipitation (ChIP) at Telomeres:

  • Immunoprecipitate with ZSCAN16 antibody

  • Use telomere-specific primers for qPCR

  • Alternatively, perform ChIP-seq and analyze telomeric reads

• Telomere Length Analysis:

  • Manipulate ZSCAN16 expression via knockdown or overexpression

  • Measure telomere length using Terminal Restriction Fragment (TRF) analysis or qPCR

  • Correlate ZSCAN16 levels with telomere length changes

• Telomerase Activity Assay:

  • Assess the impact of ZSCAN16 modulation on telomerase activity using TRAP assay

  • Determine if ZSCAN16 affects telomerase recruitment to telomeres

These approaches can help elucidate ZSCAN16's role in maintaining genome stability through telomere regulation .

What are common technical challenges with ZSCAN16 antibodies in Western blotting, and how can they be overcome?

Researchers may encounter several challenges when using ZSCAN16 antibodies:

• High Background:

  • Increase blocking time (use 5% BSA or milk for 2 hours)

  • Optimize antibody dilution (start with manufacturer's recommendation and adjust)

  • Increase washing steps (5-6 washes of 5-10 minutes each)

  • Use fresher antibody preparations

• Weak Signal:

  • Increase protein loading (30-50μg)

  • Reduce antibody dilution

  • Extend primary antibody incubation (overnight at 4°C)

  • Use enhanced chemiluminescence detection systems

  • Consider signal amplification techniques

• Non-specific Bands:

  • Validate with positive controls (NIH-3T3 and HT-29 cells have been used)

  • Use ZSCAN16 knockdown or overexpression samples as controls

  • Increase washing stringency

  • Consider using monoclonal antibodies for increased specificity

• Optimization Table for Western Blot:

Published research has successfully used extracts from NIH-3T3 cells and HT-29 cells as controls for ZNF435 (ZSCAN16) antibody validation .

How should results be interpreted when ZSCAN16 shows different expression patterns in various experimental approaches?

Discrepancies between different detection methods can occur and require careful interpretation:

• Validation Across Multiple Techniques:

  • Compare results from RT-qPCR, Western blot, and IHC

  • In HCC research, ZSCAN16 upregulation has been confirmed at both mRNA and protein levels

  • Discrepancies may indicate post-transcriptional regulation

• Cell Type-Specific Expression:

  • Compare expression across different cell lines

  • ZSCAN16 shows higher expression in HCC cell lines (Hep3B, PLC/PRF/5) compared to normal liver cells (THLE-2)

  • Document expression patterns across various tissues if working with tissue panels

• Antibody Cross-Reactivity:

  • Test antibody specificity using overexpression and knockdown controls

  • Consider using alternative antibodies that target different epitopes

  • Verify antibody specificity through immunogen competition assays

• Data Integration Approach:

  • Weight results based on assay reliability and reproducibility

  • Consider biological context and functional validation

  • Correlate with publicly available expression databases (TCGA, GEO)

Research has demonstrated consistent upregulation of ZSCAN16 in HCC using multiple detection methods, providing a benchmark for expected consistency across techniques .

How can ZSCAN16 antibodies be employed in investigating its role in cancer immunotherapy approaches?

Given the emerging importance of transcription factors in immune response modulation, ZSCAN16 antibodies can be utilized in immunotherapy research:

• Tumor Microenvironment Analysis:

  • Multiplex immunofluorescence with ZSCAN16 and immune cell markers

  • Analyze correlation between ZSCAN16 expression and immune infiltration

  • Assess impact on PD-L1 expression in tumor cells

• Response Prediction Biomarker Development:

  • Evaluate ZSCAN16 expression in pre-treatment biopsies

  • Correlate with response to immunotherapy

  • Develop IHC-based scoring system for clinical application

• Mechanistic Studies:

  • Investigate how ZSCAN16 modulation affects tumor cell recognition by immune cells

  • Analyze changes in cytokine production and secretion

  • Assess impact on antigen presentation machinery

• Combination Therapy Approaches:

  • Test ZSCAN16 inhibition in combination with immune checkpoint blockade

  • Evaluate synergistic effects with radiation therapy

  • Recent research suggests that understanding the role of factors like ZSCAN16 may improve outcomes when combining radiotherapy and immunotherapy in melanoma

What experimental approaches can elucidate the relationship between ZSCAN16 and genomic stability in cancer progression?

To investigate ZSCAN16's role in genomic stability:

• DNA Damage Response Analysis:

  • Modulate ZSCAN16 expression (knockdown/overexpression)

  • Induce DNA damage with radiation or genotoxic agents

  • Quantify γH2AX foci formation using immunofluorescence

  • Assess repair kinetics through comet assay

• Chromosomal Stability Assessment:

  • Perform karyotype analysis after ZSCAN16 manipulation

  • Quantify micronuclei formation as a marker of genomic instability

  • Analyze copy number variations using array CGH

• Telomere Dysfunction Analysis:

  • Measure telomere dysfunction-induced foci (TIFs)

  • Co-localization studies of ZSCAN16 with telomere markers

  • Analyze telomere shortening rates in ZSCAN16-depleted cells

• Experimental Workflow for Genomic Stability Assessment:

  • Establish ZSCAN16 knockdown and overexpression models

  • Challenge cells with DNA damaging agents

  • Perform comprehensive genomic stability analyses

  • Correlate findings with cancer hallmarks like invasion and metastasis

Recent research has linked ZSCAN16 to telomere maintenance and genome integrity, suggesting its involvement in preventing genomic instability during cancer development .

What are the latest methodologies for studying ZSCAN16's interaction with competing endogenous RNA networks?

Based on recent findings about ZSCAN16-AS1's role as a competing endogenous RNA, these advanced methodologies can help investigate ZSCAN16's potential interactions:

• RNA-RNA Interaction Mapping:

  • Use techniques like CLASH (crosslinking, ligation, and sequencing of hybrids)

  • Apply RNA antisense purification (RAP) to identify interacting RNAs

  • Perform RNA immunoprecipitation sequencing (RIP-seq) with ZSCAN16 antibodies

• Functional Validation Experiments:

  • Luciferase reporter assays with wild-type and mutated binding sites

  • RNA pull-down assays followed by mass spectrometry

  • RNA fluorescence in situ hybridization (FISH) to visualize co-localization

• Integrated RNA-Protein Network Analysis:

  • Combine RIP-seq, RNA-seq, and ChIP-seq data

  • Construct regulatory networks using computational approaches

  • Validate key nodes through functional experiments

• Experimental Design for ceRNA Studies:

  • Identify potential microRNA binding sites in ZSCAN16 transcripts

  • Perform miRNA inhibitor/mimic studies in conjunction with ZSCAN16 modulation

  • Validate interactions using biotin-labeled miRNA pull-down